ESMO guidelines for the treatment of metastatic colorectal cancer
Colorectal cancer is a serious health problem all over the world as well as in our country, and the Slovak Republic ranks first in terms of incidence and mortality among the countries of the European Union. The treatment of metastatic colorectal cancer has greatly improved over the past 25 years, and the median survival of patients is currently 30 months. Several factors are behind the improvement of patient prognosis, among them better follow-up after primary surgical treatment, better effectiveness of systemic treatment, use of local treatment and effective supportive treatment. ESMO guidelines from 2016 brought comprehensive guidelines that can be used in clinical practice. At the end of 2022, new ESMO guidelines were published, which capture new knowledge and patient management The aim of this review is to provide the clinician with a brief overview of guidelines and changes since 2016.